Alpine Immune Sciences, Inc. (ALPN)
ALPN moved a median of +0.05% 30 minutes after news, and 0.00% by the close. How ALPN actually reacts to news — the realized, point-in-time move the market made, measured across 171 labeled events over the last three years with zero look-ahead.
ALPN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 43% | 129 |
| 30-min | +0.05% | 54% | 129 |
| 60-min | +0.23% | 64% | 129 |
| to close | 0.00% | 47% | 129 |
| Middle 50% of ALPN reactions | -0.71% to +1.04% |
|---|---|
| Median reaction (30-min) | +0.05% |
| Measured reactions | 171 |
Half of all Alpine Immune Sciences, Inc. news events land between -0.71% and +1.04% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALPN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 14 | +0.20% | 100% | +0.34% |
| Coverage initiations | 13 | -1.09% | 31% | -0.56% |
| Rating reiterations | 23 | +0.20% | 78% | +0.34% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how ALPN ranks against every other measured name →
That’s how ALPN usually reacts — get an email when it moves on news →Email me when ALPN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALPN's baseline. Nothing else.
Recent ALPN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners | Press release | Business Wire | — | — | |
| Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors | Press release | GlobeNewswire | — | — | |
| Form 15-12G ALPINE IMMUNE SCIENCES, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT ALPINE IMMUNE SCIENCES, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: May 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM ALPINE IMMUNE SCIENCES, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS ALPINE IMMUNE SCIENCES, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Alpine Immune Sciences Reports First Quarter 2024 Financial Results | Press release | Business Wire | -0.01% | +0.00% | |
| Form 10-Q ALPINE IMMUNE SCIENCES, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.01% | +0.00% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: May 09 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | +0.00% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRC, HRT, ALPN, MCBC | Press release | PR Newswire | +0.01% | -0.12% | |
| Form 10-K/A ALPINE IMMUNE SCIENCES, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.01% | -0.06% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIRC, ALPN, WIRE | Press release | PR Newswire | -0.01% | -0.12% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, LABP, SWAV, FUSN | Press release | Accesswire | +0.08% | -0.05% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN | Press release | PR Newswire | -0.01% | -0.03% | |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, JBT, ELYM, HRT | Press release | Accesswire | +0.12% | +0.02% | |
| Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy | Press release | Business Wire | -0.02% | +0.34% | |
| ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.02% | +0.34% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | +0.34% | |
| Vertex Enters Into Agreement to Acquire Alpine Immune Sciences | Press release | Business Wire | -0.02% | +0.34% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | +10.62% | |
| Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024 | Press release | Business Wire | -2.67% | +2.31% | |
| Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024 | Press release | Business Wire | -0.05% | +2.69% | |
| Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference | Press release | Business Wire | -0.05% | +2.69% | |
| Form 10-K ALPINE IMMUNE SCIENCES, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.31% | -0.15% | |
| Form S-8 ALPINE IMMUNE SCIENCES, | SEC filing · Form S-8 | SEC EDGAR | +2.31% | -0.15% | |
| Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results | Press release | Business Wire | +7.29% | +6.82% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +7.29% | +6.82% | |
| Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results | Press release | Business Wire | +1.15% | -4.24% | |
| Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences | Press release | Business Wire | +4.01% | +2.71% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +4.56% | |
| Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences | Press release | Business Wire | -0.61% | -0.97% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Jan 04 | SEC filing · Form 8-K | SEC EDGAR | -0.84% | +5.67% | |
| Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie | Press release | Business Wire | +0.52% | -3.77% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Dec 20 | SEC filing · Form 8-K | SEC EDGAR | +0.52% | -3.77% | |
| Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -0.42% | +4.40% | |
| Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference | Press release | Business Wire | +0.00% | -3.79% | |
| Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 | Press release | Business Wire | +3.22% | -0.94% | |
| Alpine Immune Sciences Reports Third Quarter 2023 Financial Results | Press release | Business Wire | +3.22% | -0.94% | |
| Form 10-Q ALPINE IMMUNE SCIENCES, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.22% | -0.94% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +3.22% | -0.94% | |
| Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 | Press release | Business Wire | -2.40% | -4.15% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | -2.54% | |
| Alpine Immune Sciences Announces Pricing of $150 Million Public Offering | Press release | Business Wire | +3.93% | +5.18% | |
| Alpine Immune Sciences Announces Proposed Public Offering | Press release | Business Wire | -1.19% | -11.69% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -1.19% | -11.69% | |
| Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting | Press release | Business Wire | -1.02% | +2.62% | |
| Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023 | Press release | Business Wire | -0.81% | +8.63% | |
| Form 8-K ALPINE IMMUNE SCIENCES, For: Nov 02 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | +8.63% | |
| Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 | Press release | Business Wire | +1.44% | +4.38% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALPN section they belong to.
Where else ALPN is measured.
ALPN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Exicure, Inc. (XCUR) | 173 | 0.00% | 49% |
| Aytu BioPharma, Inc. (AYTU) | 172 | -0.14% | 40% |
| NuCana plc - American Depositary Shares (NCNA) | 171 | -1.28% | 40% |
| UCB SA NPV (UCBJF) | 171 | 0.00% | 3% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alpine Immune Sciences, Inc.'s median reaction calculated?
Every labeled ALPN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 171 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of ALPN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALPN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.